Calculated
DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
132.92 USD164.45 USD194.10 USD
+38.15%
164.45 USDCurrent price is 38.2% above the base model value.
J
HealthcareDrug Manufacturers - GeneralUnited States
Johnson & Johnson (JNJ) Valuation Assumptions
Review Johnson & Johnson (JNJ) valuation assumptions across intrinsic value, DCF, reverse DCF implied growth, EV/EBITDA, P/FCF, and financial trends.
NYQ · US · USD
Latest price227.19 USD
30D-6.18%
Price vs model median+149%Model median is the median base output from applicable absolute models, excluding Reverse DCF.
Quick answer
What growth is the market currently pricing into JNJ?
At 227.19 USD, TickerVal's reverse DCF setup implies roughly 10.4% annual FCF growth for 10 years for JNJ, using the current normalized FCF base, a 9% discount rate, and 3.0% terminal growth. The rest of the page shows valuation assumptions, model differences, and source-data context for research reference.
What price implies
What does the current price imply?
At 227.19 USD, the model implies roughly 10.41% annual FCF growth for 10 years, with required long-term operating margin near 24.96% and terminal growth around 3%. This module is a research reference.
Implied FCF CAGR10.41%
10-year Reverse DCF scenario
Required long-term operating margin24.96%
Five-year median × 0.95
Implied terminal growth3%
From current model assumptions
Discount rate assumption9%
Estimated from current sector rules
Adjust assumptions+
Adjust assumptions
Move assumptions to see how the current price implied conditions change.
Forecast horizon10Y
Historical implied expectations
How does today's implied growth compare with history?
Calculated from selected historical prices and current normalized FCF assumptions, not a full point-in-time backtest.
Current implied FCF CAGR10.4%
5Y monthly median5.16%
Current vs 5Y median+5.24 pts
Showing 8 of 13 report price anchors
| Report price anchor | Price date | Anchor price | Implied FCF CAGR |
|---|---|---|---|
| Q1-2026 | 2026/03/31 | 244.44 USD | 11.37% |
| FY2025 | 2025/12/31 | 205.86 USD | 9.12% |
| Q4-2025 | 2025/12/31 | 205.86 USD | 9.12% |
| Q3-2025 | 2025/09/30 | 183.28 USD | 7.6% |
| Q2-2025 | 2025/06/30 | 149.88 USD | 4.97% |
| Q1-2025 | 2025/03/31 | 161.34 USD | 5.94% |
| FY2024 | 2024/12/31 | 139.58 USD | 4.04% |
| Q3-2025 | 2024/12/30 | 138.35 USD | 3.93% |
202610.56%
Avg 10.85% · Samples 5
20255.95%
Avg 6.54% · Samples 12
20244.93%
Avg 4.75% · Samples 12
20234.6%
Avg 4.63% · Samples 12
Historical valuation multiples
How have EV/EBITDA and P/FCF changed over the last 5 years?
Annual fiscal-period anchored: month-end prices are paired with the most recent annual fiscal period ending on or before each date, covering the last 5 years (41 monthly samples). Multiples are research references; financial-sector or otherwise non-comparable companies require sector-specific context.
P/E
Market cap divided by reported net income (annual fiscal-period snapshot).
20.6x
Near median · P35
Current5Y medianTypical range IQR
5Y median21.5x
Current20.6x · P35
5Y low 9.93xCurrent vs median-4.2%5Y high 35.55x
IQR 11.58–25.36x · 41 monthly samples
P/FCF
Market cap divided by reported free cash flow.
28.59x
Above history · P91
Current5Y medianTypical range IQR
5Y median21.99x
Current28.59x · P91
5Y low 18.78xCurrent vs median+30%5Y high 31.26x
IQR 21.01–23.66x · 41 monthly samples
Month-end historical multiples
A date-friendly view for historical EV/EBITDA, P/FCF, and P/E queries.
Showing 8 of 41 month-end samples
| Month-end | Price | P/E | P/FCF | EV/EBITDA | Fiscal period used |
|---|---|---|---|---|---|
| 2026-05-01 | 227.19 USD | 20.6x | 28.59x | - | 2025-12-31 |
| 2026-04-30 | 229.85 USD | 20.84x | 28.92x | - | 2025-12-31 |
| 2026-03-31 | 244.44 USD | 22.16x | 30.76x | - | 2025-12-31 |
| 2026-02-27 | 248.43 USD | 22.52x | 31.26x | - | 2025-12-31 |
| 2026-01-30 | 226.05 USD | 20.49x | 28.44x | - | 2025-12-31 |
| 2025-12-31 | 205.86 USD | 18.66x | 25.9x | - | 2025-12-31 |
| 2025-11-28 | 205.83 USD | 35.55x | 27.69x | - | 2024-12-31 |
| 2025-10-31 | 186.69 USD | 32.24x | 25.11x | - | 2024-12-31 |
Valuation overview
How do the valuation assumptions fit together?
Johnson & Johnson (JNJ) valuation on TickerVal is designed to help readers understand the operating expectations embedded in the current market price. At 227.19 USD, the page brings intrinsic value analysis, DCF outputs, reverse DCF implied growth, EV/EBITDA, P/FCF, and valuation assumptions into one research view within the Healthcare sector and the Drug Manufacturers - General industry. Instead of treating one model as a final answer, TickerVal compares cash-flow, earnings-power, balance-sheet, and relative-multiple lenses so the differences between models are visible. The reverse DCF view currently shows implied growth of 10.4%, while the model median reference sits at +149% versus the current price. The DCF and reverse DCF sections focus on free cash flow, discount rate, terminal growth, and the long-term growth path implied by the current price. EV/EBITDA and P/FCF provide additional context for capital structure and cash-flow multiples. The financial trends section connects those valuation assumptions back to reported revenue of 94B USD, free cash flow of 19B USD, margins, and balance-sheet facts from public filings. Readers can use the layout to compare assumptions across models before reviewing the underlying source data. This page is intended for transparent research reference, model review, and assumption checking.
Valuation model range vs. current price
Each row shows a model output range, with a vertical line for the current price.
DCFCalculated
132.92 USD-194.10 USD
Earnings Power ValueCalculated
70.09 USD-70.09 USD
Graham NumberCalculated · Limited reference
91.26 USD-91.26 USD
Current price reference line
Why do valuation models give different answers?
Different models rely on different financial facts. The status blocks show which lenses fit this page data.
| Model | Fit | Context |
|---|---|---|
| DCF | Suitable | Useful when recurring free cash flow history exists; sensitive to growth and discount assumptions. |
| Owner Earnings | Not meaningful | Useful when net income, D&A, and capex support owner-earnings scenarios. |
| Reverse DCF | Suitable | Shows the FCF growth implied by current price under stated assumptions. |
| Earnings Power Value | Suitable | Useful for mature operating profit, with limited emphasis on growth. |
| Graham Number | Limited | Works best when EPS and book value are both positive. |
| Dividend Discount Model | Not meaningful | Needs explicit dividend history, which is not included in the current version. |
| Net-Net Liquidation Value | Not meaningful | Requires current asset and liability detail beyond the current data set. |
| PEG | Limited | A quick growth multiple lens when EPS history is positive. |
| EV/EBITDA | Limited | Useful for capital structure context when operating profit is available. |
| P/FCF | Limited | A compact free-cash-flow multiple view for positive FCF years. |
| P/B | Limited | More useful for asset-heavy balance sheets than asset-light companies. |
| P/S | Limited | A revenue multiple lens when profit or FCF is not stable. |
| Peer Comparison | Not meaningful | Standardized peer comparisons are not included in the current version. |
Which valuation models are being calculated?
Hover each model row to inspect formulas and inputs.
Current price227.19 USD
Model median reference91.26 USD
Price vs model median+149%
Price date2026/05/01
91.26 USD91.26 USD91.26 USD
+149%
Excluded
Owner Earnings
Uses net income, D&A, and capex as an owner-earnings proxy.
---
-Owner earnings samples are insufficient.
Calculated
Reverse DCF
Solves the forward FCF growth rate implied by the current price.
Implied growth10.4%
Current price implies roughly 10.4% annualized FCF growth.
10.4%Current price implies roughly 10.4% annualized FCF growth.
Calculated
Earnings Power Value
Estimates earnings power value without assuming growth.
70.09 USD70.09 USD70.09 USD
+224%
70.09 USDCurrent price is 224.1% above the base model value.
Updated: 2026/05/03
Which financial trends support the assumptions?
Annual financial metrics with switchable views. · Unit: USD
FY2025 · Dec 2025 report13 records
Revenue94B USD
Net income27B USD
Free cash flow19B USD
CapEx-5B USD
Operating cash flow25B USD
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
ExpandCollapse
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/12/31 | Asset impairment | Impairment | -64M USD | Medium |
| 2025/12/31 | Asset sale gain/loss | Asset sale gain/loss | 316M USD | Medium |
| 2025/12/31 | Other special charges | Other | -5B USD | Medium |
| 2025/12/31 | Restructuring and merger costs | Restructuring | -338M USD | Medium |
| 2025/12/31 | Special income/charges | Other | 4B USD | Medium |
| 2024/12/31 | Asset impairment | Impairment | -167M USD | Medium |
| 2024/12/31 | Asset sale gain/loss | Asset sale gain/loss | -237M USD | Medium |
| 2024/12/31 | Other special charges | Other | -4B USD | Medium |
| 2024/12/31 | Restructuring and merger costs | Restructuring | -817M USD | Medium |
| 2024/12/31 | Special income/charges | Other | -5B USD | Medium |
| 2022/12/31 | Asset impairment | Impairment | -619M USD | Medium |
| 2022/12/31 | Asset sale gain/loss | Asset sale gain/loss | -553M USD | Medium |
| 2022/12/31 | Other special charges | Other | -2B USD | Medium |
| 2022/12/31 | Restructuring and merger costs | Restructuring | -217M USD | Medium |
| 2022/12/31 | Special income/charges | Other | -836M USD | Medium |
| 2026/03/31 | Other special charges | Other | -237M USD | Medium |
| 2026/03/31 | Restructuring and merger costs | Restructuring | -104M USD | Medium |
| 2026/03/31 | Special income/charges | Other | -370M USD | Medium |
| 2026/03/31 | Write-off | Impairment | -28M USD | Medium |
| 2025/12/31 | Asset sale gain/loss | Asset sale gain/loss | 79M USD | Medium |
| 2025/12/31 | Other special charges | Other | -711M USD | Medium |
| 2025/12/31 | Restructuring and merger costs | Restructuring | -92M USD | Medium |
| 2025/12/31 | Special income/charges | Other | -683M USD | Medium |
| 2025/09/30 | Asset sale gain/loss | Asset sale gain/loss | 316M USD | Medium |
| 2025/09/30 | Restructuring and merger costs | Restructuring | -129M USD | Medium |
| 2025/09/30 | Special income/charges | Other | -129M USD | Medium |
| 2025/06/30 | Other special charges | Other | -237M USD | Medium |
| 2025/06/30 | Restructuring and merger costs | Restructuring | -130M USD | Medium |
| 2025/06/30 | Special income/charges | Other | -367M USD | Medium |
| 2025/03/31 | Other special charges | Other | -6B USD | Medium |
| 2025/03/31 | Restructuring and merger costs | Restructuring | -92M USD | Medium |
| 2025/03/31 | Special income/charges | Other | 5B USD | Medium |
| 2024/09/29 | Asset impairment | Impairment | -299M USD | Medium |
| 2024/09/29 | Restructuring charges | Restructuring | -184M USD | Medium |
| 2024/06/30 | Asset impairment | Impairment | -299M USD | Medium |
| 2024/06/30 | Restructuring charges | Restructuring | -130M USD | Medium |
Ad placement
Which reported financials feed the models?
Financial DetailsShowing latest 5 / 13
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/12/31 | Annual | 94B USD | 27B USD | 27B USD | 19B USD | 11.03 | 11.23 |
| 2024/12/31 | Annual | 89B USD | 14B USD | 25B USD | 18B USD | 5.79 | 10.27 |
| 2023/12/31 | Annual | 85B USD | 35B USD | 19B USD | 18B USD | 13.72 | 7.09 |
| 2022/12/31 | Annual | 80B USD | 18B USD | 22B USD | 17B USD | 6.73 | 8.33 |
| 2021/12/31 | Annual | - | - | - | - | - | - |
Where does this data come from?
Open to inspect field-level SEC EDGAR source, filing form, and derived notes.
SEC EDGAR
Where does this data come from?
Open to inspect field-level SEC EDGAR source, filing form, and derived notes.
Frequently asked questions
Quick notes on price-implied expectations, model differences, and source data.
What is Johnson & Johnson's intrinsic value?
Johnson & Johnson's intrinsic value on TickerVal is reviewed through DCF outputs, reverse DCF implied growth, EV/EBITDA, P/FCF, valuation assumptions, and financial trends from public filings.
How is JNJ valued on TickerVal?
TickerVal values JNJ by comparing intrinsic value models, DCF and reverse DCF assumptions, cash-flow multiples, earnings-power references, and reported financial trends.
What does the current stock price imply?
The reverse DCF view estimates the free-cash-flow growth path implied by the current stock price under stated discount-rate and terminal-growth assumptions.
Which valuation models are used?
TickerVal uses DCF, reverse DCF, Owner Earnings, EPV, Graham Number, EV/EBITDA, P/FCF, P/B, P/S, and other model references where the underlying data is available.
Is this investment advice?
No. TickerVal does not provide investment advice, ratings, price targets, or buy/sell recommendations.
Early supporter list
Get notified as TickerVal adds saved assumptions.
Join the research reference list for product updates, model notes, and transparent assumption workflows.
Ad placement